Podcast Categories: Crux of MedTech

In this episode, host Henry Norton sits down with Iwan van Vijfeijken, CEO of Microsure and a four-time medtech entrepreneur who’s been through the full cycle of startup life. Iwan made the jump from NXP Semiconductors to medtech 15 years ago, starting as employee number one at Dermasun Medical. Since then, he’s navigated three more… Continue reading Venture is first and foremost an Adventure with Iwan van Vijfeijken

In this episode, host Henry Norton sits down with Gautam Kainth, Partner at TCP Health Ventures, to unpack why medtech investing fundamentally differs from traditional tech and what founders need to know about positioning their companies for strategic exits. Gautam brings over 20 years of investment experience with $1+ billion in deployed capital across 30+… Continue reading Building Acquisition-Ready Medtech from Series A with Gautam Kainth

Raymond Cohen has spent 40+ years in medtech, never at a big company but always building. After taking Axonics from whiteboard to $500M in revenue and a Boston Scientific exit, he’s now chairman of multiple high-growth ventures. In this episode, he breaks down what actually makes a company acquirable, why founders need to get over… Continue reading 100% of Nothing is Nothing with Raymond Cohen

John Murphy left a corporate COO role to become employee number one at Virtual Incision then spent the next 14 years building MIRA, the world’s first miniaturised soft tissue surgical robot. The pitch? A little robot on the inside, instead of a big one reaching in from the outside. The journey included five alpha iterations,… Continue reading 30 Da Vinci Copycats Will Fail with John Murphy

Alan Cohen has built companies, sold companies, started a price war between tech giants and now invests in what he calls “tech med” at DCVC, a $4.5bn deep-tech fund. The distinction matters: tech med starts with data and computational methods, not hardware. In this conversation, Alan unpacks the investments that excite him, from real-time surgical… Continue reading 10x Isn’t Enough to Change Medicine with Alan Cohen

In this episode, Henry Norton sits down with Mark Tapsak, Chief Science Officer at Glucotrack and one of Dexcom’s earliest employees. Mark Tapsak left Medtronic for a “crazy startup” called Dexcom after seeing data so compelling he couldn’t say no. Two decades later, he’s back in the CGM game as Chief Science Officer at Glucotrack,… Continue reading The Glucose Sensor That Predicts the Future with Mark Tapsak

In this episode, Henry Norton sits down with Robert Kieval, CEO of Arctx Medical Inc, to talk about a condition that sends 300,000 Americans to the ER every year with no approved treatment options waiting for them. Robert shares how Arctx is developing a deceptively simple solution: a cooling catheter that targets pancreatic inflammation from… Continue reading Cooling the Pancreas to Save Lives with Robert Kieval

In this episode of The Crux of MedTech, host Henry Norton sits down with Andrew Glass, CEO of Vivasure Medical, fresh off announcing the company’s acquisition by Haemonetics Corporation. Andrew shares the full journey, from his early days in drug-eluting stents at Guidant (later Abbott), to running a $10M sales territory, to making equity investments… Continue reading Vivasure Exits to Haemonetics for €185 Million, an Interview with Andrew Glass

In this episode of the Cruxx of MedTech podcast, host Henry Norton sits down with Ananth Ravi, founder of MOLLI Surgical to unpack the full journey from hospital research lab to acquisition by Stryker. Ananth shared the origin story behind MOLLI, a GPS-guided surgical system that replaced painful wire localisation with a tiny radioactive seed… Continue reading From Research Bench to Exit with Ananth Ravi

In this Crux of Medtech crossover with the new Crux of Cardio series, Jordan and Henry sit down with Jack, his wife and caregiver Rocky, and SynCardia CEO Patrick Schnegelsberg to explore what a total artificial heart really means at the bedside and in the boardroom.